# Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

> **NCT04790448** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 37 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Irinotecan
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT04790448
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-27
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04790448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04790448, "Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04790448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*